Literature DB >> 28245458

Endocrine Autoimmunity in Down's Syndrome.

Federica Guaraldi, Ruth Rossetto Giaccherino, Fabio Lanfranco, Giovanna Motta, Davide Gori, Emanuela Arvat, Enzio Ghigo, Roberta Giordano.   

Abstract

Since the mid 1900s, a significant increase of infectious, hematological, and autoimmune diseases has been reported in patients with Down's syndrome (DS), independent of sex, age, family history, and exposure to other risk factors, suggesting an intrinsic alteration of the immune system. Several in vitro and in vivo studies have demonstrated alterations of both cellular and humoral immunological response mainly, although not exclusively, secondary to alterations of the expression of autoimmune regulator gene (located on chromosome 21), leading to thymic structural and functional impairments. Autoimmune thyroid disorders (i.e. Hashimoto's thyroiditis and Graves' disease) and type 1 diabetes mellitus are the most common autoimmune endocrine disorders associated with DS, and present with some peculiar features. The underlying etiopathogenic mechanisms and clinical significance of some mild laboratory alterations are still poorly understood. For these aspects, together with the associated multiple comorbidities and intellectual impairment - that make DS patients dependent on care givers - and in the absence of definite guidelines, disease management is very challenging and should be patient-tailored.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28245458     DOI: 10.1159/000452912

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  10 in total

Review 1.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

2.  Prevalence of Common Disease Conditions in a Large Cohort of Individuals With Down Syndrome in the United States.

Authors:  Brian Chicoine; Anne Rivelli; Veronica Fitzpatrick; Laura Chicoine; Gengjie Jia; Andrey Rzhetsky
Journal:  J Patient Cent Res Rev       Date:  2021-04-19

3.  Prevalence of Endocrine Disorders Among 6078 Individuals With Down Syndrome in the United States.

Authors:  Anne Rivelli; Veronica Fitzpatrick; Danielle Wales; Laura Chicoine; Gengjie Jia; Andrey Rzhetsky; Brian Chicoine
Journal:  J Patient Cent Res Rev       Date:  2022-01-17

Review 4.  Down syndrome, accelerated aging and immunosenescence.

Authors:  Noémie Gensous; Maria Giulia Bacalini; Claudio Franceschi; Paolo Garagnani
Journal:  Semin Immunopathol       Date:  2020-07-23       Impact factor: 9.623

5.  Endocrinal dysfunction in children with Down syndrome.

Authors:  Kotb Abbass Metwalley; Hekma Saad Farghaly
Journal:  Ann Pediatr Endocrinol Metab       Date:  2022-03-31

6.  Hospital admissions in infants with Down syndrome: a record-linked population-based cohort study in Wales.

Authors:  R A Esperanza; A Evans; D Tucker; S Paranjothy; L Hurt
Journal:  J Intellect Disabil Res       Date:  2021-12-03

Review 7.  Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome.

Authors:  Elizabeth J Andrews; Alessandra C Martini; Elizabeth Head
Journal:  Front Neurosci       Date:  2022-08-12       Impact factor: 5.152

Review 8.  Thyroid Disorders in Subjects with Down Syndrome: An Update.

Authors:  Nermine H Amr
Journal:  Acta Biomed       Date:  2018-03-27

9.  Neuroinflammatory Markers in the Serum of Prepubertal Children with Down Syndrome.

Authors:  Luigi Tarani; Valentina Carito; Giampiero Ferraguti; Carla Petrella; Antonio Greco; Massimo Ralli; Marisa Patrizia Messina; Debora Rasio; Enrica De Luca; Carolina Putotto; Paolo Versacci; Mauro Ceccanti; Marco Fiore
Journal:  J Immunol Res       Date:  2020-03-23       Impact factor: 4.818

Review 10.  Autoimmune Thyroid Disease in Specific Genetic Syndromes in Childhood and Adolescence.

Authors:  Eleni Magdalini Kyritsi; Christina Kanaka-Gantenbein
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-19       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.